Navigation Links
Results of the EVOLVE trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Durable polymer coatings on drug-eluting stents have been associated with chronic inflammation and impaired healing. Bioabsorbable polymer-coated drug-delivery systems may reduce the risk of late events, including stent thrombosis, and the need for prolonged dual antiplatelet therapy.

The EVOLVE trial is a prospective, multi-center, randomized, single blind, first in-human non-inferiority trial. Subjects were randomized 1:1:1 to either of two formulations of a stent (full or one-half dose) with the bioabsorbable polymer and a standard drug-eluting stent.

The primary clinical endpoint was the 30-day rate of target lesion failure, defined as cardiac death related to the target vessel (TV), myocardial infarction related to the TV, or target lesion revascularization. The primary angiographic endpoint was 6-month in-stent late loss.

A total of 291 subjects were enrolled in the EVOLVE trial between July 29, 2010 and January 20, 2011 at 29 sites in Europe, Australia, and New Zealand. The mean subject age was 63 years, 73.1% were male, and 19.3% had medically treated diabetes.

In the bioabsorbable stent group with the full dose (n= 94), late loss at six months was .10 mm and 30-day target lesion failure was 1.1%. In the bioabsorbable stent group with dose (n=99), late loss at six months was 0.13 mm and 30-day target lesion failure was 3.1%.

These results compare to the use of a traditional drug-eluting stent (n=98), in which late loss at 6 months was .15 mm and 30-day target lesion failure was 0%.

"Clinical events were low and comparable with no stent thromboses in any group," said lead investigator, Ian T. Meredith, MBBS, PhD. Dr. Meredith is Professor and Director of Monash HEART and Executive Director of Monash Cardiovascular Research Centre at Monash Medical Centre and Monash University in Melbourne, Australia.

"These results support the safety and efficacy of the novel abluminal bioabsorbable polymer everolimus-eluting stent for the treatment of patients with de novo coronary artery disease. Additional research is needed to evaluate clinical event rates and the potential for dual antiplatelet therapy reduction with this novel stent. " said Prof. Meredith.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the REMEDEE trial reported at TCT 2011
2. Results of the NEXT clinical trial Reported at TCT 2011
3. Results of the PEPCAD-DES trial reported at TCT 2011
4. Results of the STACCATO Trial reported at TCT 2011
5. Results of the DEB-AMI Trial reported at TCT 2011
6. Results of the RIFLE STEACS clinical trial reported at TCT 2011
7. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
8. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
9. Combination epigenetic therapy clinical trial results
10. Results of the PARIS registry Reported at TCT 2011
11. Results of the TRIGGER-PCI trial reported at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... , ... Recognizing that lifestyle medicine is essential to health and healthcare, ... Katz, MD, MPH, president of the American College of Lifestyle Medicine, as their first ... gratifying,” said Katz. “There is so much opportunity to add years to lives, and ...
(Date:5/4/2016)... ... ... The preeminent surgical aftercare facility Pearl Recovery Retreat was pleased to provide ... 2016, the 61-year-old model and reality TV star was diagnosed with early stage ductal ... according to an interview with the Daily Mail Online . , Following ...
(Date:5/4/2016)... , ... May 04, 2016 ... ... compression and support for knees, ankles, and elbows. Engineered with athletes in ... 3D flat-bed manufacturing (opposed to ineffective circular knitting, common in the industry) ...
(Date:5/4/2016)... Angeles, California (PRWEB) , ... May 04, 2016 , ... ... Cancer Research (AACR) honors the month of May as National Cancer Research Month. According ... 1.6 million new diagnoses of cancer with predications of one in four Americans dying ...
(Date:5/4/2016)... ... 04, 2016 , ... International Conference on Obesity and Chronic ... at Las Vegas. It aims to bring together academicians, scientists, dietitians, surgeons, physicians, ... across the globe; making the conference a perfect platform to share experience and ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology: